Listed below are a few highlights of the most impactful technology to be developed at UTHealth Houston and then licensed by OTM to companies around the world. Here's looking towards your technology and hopes that over time, we can add it to this list!
Texas Therapeutics Institute
Under Dr. Zhiqiang An’s leadership, TTI has built a major platform for the discovery of monoclonal antibody-based therapeutics, targeting cancer, metabolic diseases, spinal cord injury, neurodegenerative diseases, fibrosis, liver injury, and viral infections.
- $11M+ in revenue to UTHealth
- 30 active drug discovery projects
- 14 drug candidates in clinical development
- 7 startup companies
- 33 option or license agreements
A Lyme Disease Diagnostic
Dr. Steve Norris and colleagues revolutionized the diagnosis of Lyme disease through discovery of a VlsE diagnostic assay. The initial patent family expired in 2017, and the remaining patent family is expected to expire in the next few years.
- $65M+ in revenues to UTHealth; $1.6B+ in sales
- 16 Issued US Patents
- 25 options or license agreements
- 17 companies sold/are selling the technology
Elastography
A technique pioneered by Dr. Jon Ophir, elastography is the imaging of the elastic properties of soft tissues using ultrasound to enable detection of breast, prostate, thyroid and cervical cancer. The patents for this technology expired between 2012 and 2022.
- $3.9M+ in revenue to UTHealth
- 10 Issued US Patents
- 11 options or license agreements
- 8 companies sold/are selling the technology (incl. GE, Siemens)
TPRI & Tejas LEE
The TPRI & Tejas LEE kindergarten through third grade reading assessments were developed by UTHealth’s Children’s Learning Institute and The University of Houston.
- $8M+ in revenue to UTHealth
- 36 license agreements to date
- 17 companies sold/are selling products
- 15M+ students impacted in US (not including TX)